Investors

Date	Name	Title	Type	Shares Traded	Price Range
Oct 14, 2011	goldstein joseph l	Director	Option Execute	10,000	23.84
Sep 20, 2011	goldstein joseph l	Director	Acquisition (Non Open Market)	10,000	n/a
Jan 19, 2012	goldstein joseph l	Director	Automatic Sell	10,000	80.00
Mar 15, 2012	goldstein joseph l	Director	Automatic Sell	10,000	110.77 - 115.00
Mar 15, 2012	goldstein joseph l	Director	Option Execute	10,000	18.61
Sep 1, 2011	larosa joseph j	Officer	Acquisition (Non Open Market)	10,000	n/a
Jan 7, 2011	roberts william	Officer	Option Execute	10,000	9.49
Jun 14, 2010	ryan arthur f	Director	Buy	10,000	26.98
Aug 10, 2012	ryan arthur f	Director	Sell	10,000	136.15
Nov 1, 2012	ryan arthur f	Director	Sell	10,000	145.57
Feb 26, 2013	shooter eric m	Director	Acquisition (Non Open Market)	10,000	n/a
Feb 26, 2013	shooter eric m	Director	Sell	10,000	160.00
Oct 2, 2007	shooter eric m	Director	Sell	10,000	18.30 - 18.37
Oct 2, 2007	shooter eric m	Director	Option Execute	10,000	7.66
May 6, 2013	shooter eric m	Director	Acquisition (Non Open Market)	10,000	n/a
May 6, 2013	shooter eric m	Director	Sell	10,000	258.78 - 264.18
Nov 13, 2009	sing george l	Director	Buy	10,000	18.78
Dec 17, 2012	sing george l	Director	Disposition (Non Open Market)	10,000	n/a
Dec 17, 2012	sing george l	Director	Acquisition (Non Open Market)	10,000	n/a
Sep 19, 2008	kolinski stuart	Officer	Sell	9,992	23.40 - 23.69
Showing 321-340 of 639 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  See Previous 20 | See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.